FormsNet3 - Blank Form


 

Registry Use Only 
 
Sequence Number:    

 
 
Date Received: __ __ __ __ - __ __- __ __  

 
 
CIBMTR Center Number:    

 
 
CIBMTR Recipient ID:    

 
 
Today's Date: __ __ __ __ - __ __- __ __  

 
 
Date of HSCT for which this form is being completed: __ __ __ __ - __ __- __ __  

 

HSCT type (check all that apply): 

 
  

gfedcb
Autologous

 
 

  
gfedcb

Allogeneic, unrelated

 
 

  
gfedcb

Allogeneic, related

 
 

  
gfedcb

Syngeneic (identical twin)

 

Product type (check all that apply): 

 
  

gfedcb
Marrow

 
 

  
gfedcb

PBSC

 
 

  
gfedcb

Cord blood

 
 

  
gfedcb

Other product

 
 
Specify:    

 
 

  
gfedcb

If this is a report of a second or subsequent transplant, check here and continue with question 117.

 
 
1  What was the date of pathologic diagnosis of Testicular Cancer? __ __ __ __ - __ __- __ __  

 

Specify the origin of the primary tumor at diagnosis:  
 

2  Testicular primary

    
 nmlkji

yes  
 nmlkji

no  

 
 

3  Extra-gonadal germ cell tumor

    
 nmlkji

yes  
 nmlkji

no  

 

Specify site(s) of extra-gonadal germ cell tumor: 
 

4  Abdominal nodes

    
 nmlkji

yes  
 nmlkji

no  

 
 

5  Bone

    
 nmlkji

yes  
 nmlkji

no  

 
 

6  Central nervous system (CNS)

    
 nmlkji

yes  
 nmlkji

no  

 
 

7  Liver

    
 nmlkji

yes  
 nmlkji

no  

 
 

8  Lung, parenchymal

    
 nmlkji

yes  
 nmlkji

no  

 
 

9  Mediastinum

    
 nmlkji

yes  
 nmlkji

no  

  Key Fields 

Disease Assessment at Diagnosis Questions: 1 - 34

Form 2022 R2.0: Testicular/Germ Cell Cancer Pre-HSCT Data  
Center:  CRID: 

               CIBMTR Form 2022 revision 2.0 last updated July 2007  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 1 / 10



 
 

10  Testis

    
 nmlkji

yes  
 nmlkji

no  

 
 

11  Other site:

    
 nmlkji

yes  
 nmlkji

no  

 
 
12  Specify tumor site:    

 

Specify the testicular cancer histology at diagnosis: 
 

13  Choriocarcinoma

    
 nmlkji

yes  
 nmlkji

no  

 
 

14  Embryonal carcinoma

    
 nmlkji

yes  
 nmlkji

no  

 
 

15  Mixed non-seminoma

    
 nmlkji

yes  
 nmlkji

no  

 
 

16  Seminoma

    
 nmlkji

yes  
 nmlkji

no  

 
 

17  Teratoma

    
 nmlkji

yes  
 nmlkji

no  

 
 

18  Yolk sac

    
 nmlkji

yes  
 nmlkji

no  

 
 

19  Other histology

    
 nmlkji

yes  
 nmlkji

no  

 
 
20  Specify histology:    

 

Specify the tumor mass classification at diagnosis: 
 

21  Seminoma (must have normal levels of alpha-fetoprotein (AFP))

    
 nmlkji

yes  
 nmlkji

no  

 
 

22  Specify prognosis:

    
 nmlkji

good prognosis - no nonpulmonary visceral metastasis  

 nmlkji
intermediate prognosis  

 
 

23  Non-seminoma

    
 nmlkji

yes  
 nmlkji

no  

 
24  Specify prognosis:

    
 nmlkji

good prognosis - requires all of the following: • AFP < 1,000 ng/ml, HCG < 5,000 IU/L, and LDH < 1.5x upper limit of normal • nonmediastinal primary mass • no 
nonpulmonary visceral metastasis  

 nmlkji
intermediate prognosis - requires all of the following: • AFP= 1,000-10,000 ng/mL, HCG = 5,000-50,000 IU/L, or LDH = 1.5-10x upper limit of normal • nonmediastinal 

primary site • no nonpulmonary visceral metastasis  

 nmlkji
poor prognosis - any of the following: • AFP > 10,000 ng/mL, HGC > 50,000 IU/L, or LDH >10x upper limit of normal • mediastinal primary site • nonpulmonary visceral 

metastasis present  

 
 

25  Were extra-gonadal metastases present at diagnosis?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

Specify site(s) of extra-gonadal metastases present at diagnosis: 
 

26  Central nervous system

    
 nmlkji

yes  
 nmlkji

no  

Form 2022 R2.0: Testicular/Germ Cell Cancer Pre-HSCT Data  
Center:  CRID: 

               CIBMTR Form 2022 revision 2.0 last updated July 2007  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 2 / 10



 
 

27  Liver

    
 nmlkji

yes  
 nmlkji

no  

 
 

28  Lung, parenchymal

    
 nmlkji

yes  
 nmlkji

no  

 
 

29  Lymph nodes, distant

    
 nmlkji

yes  
 nmlkji

no  

 
 

30  Lymph nodes, retroperitoneal

    
 nmlkji

yes  
 nmlkji

no  

 
 

31  Pleura

    
 nmlkji

yes  
 nmlkji

no  

 
 

32  Skin

    
 nmlkji

yes  
 nmlkji

no  

 
 

33  Other site:

    
 nmlkji

yes  
 nmlkji

no  

 
 
34  Specify site:    

 

Specify the following tumor markers present prior to any first treatment for testicular cancer. 
 

35  Serum alpha-fetoprotein (AFP):

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
36     ng/mL 

 
 

37  Serum beta-human chorionic gonadotropin (βhCG):

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
38     IU/L 

 
 

39  LDH:

    
 nmlkji

Known  
 nmlkji

Not known  

  
 
40  .    

 

  
 nmlkji

U/L  
 nmlkji
µkat/L  

 
 

41  Other tumor marker?

    
 nmlkji

yes  
 nmlkji

no  

 
 
42  Specify other tumor marker:    

 
 
43  Specify value:    

 
 

44  Did the recipient undergo surgery as part of the initial disease management plan?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

Specify surgery type(s) performed: 
 

45  Biopsy only (not debulking)

    
 nmlkji

yes  
 nmlkji

no  

 
 

46  Debulking

    
 nmlkji

yes  
 nmlkji

no  

  Laboratory Studies at Diagnosis Questions: 35 - 43

  Pre-HSCT Treatment for Testicular Cancer Questions: 44 - 116

Form 2022 R2.0: Testicular/Germ Cell Cancer Pre-HSCT Data  
Center:  CRID: 

               CIBMTR Form 2022 revision 2.0 last updated July 2007  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 3 / 10



 
 

47  Orchiectomy only

    
 nmlkji

yes  
 nmlkji

no  

 
 

48  Removal of extra-abdominal metastatic lesion

    
 nmlkji

yes  
 nmlkji

no  

 
 

49  Unilateral retroperitoneal lymph node dissection and orchiectomy

    
 nmlkji

yes  
 nmlkji

no  

 
 

50  Other surgery

    
 nmlkji

yes  
 nmlkji

no  

 
 
51  Specify surgery:    

 

Specify the following tumor markers determined after surgery was performed: 
 

52  Serum alpha-fetoprotein (AFP):

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
53  .    ng/mL 

 
 

54  Serum beta-human chorionic gonadotropin (βhCG):

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
55  .    IU/L 

 
 

56  LDH:

    
 nmlkji

Known  
 nmlkji

Not known  

  
 
57  .    

 

  
 nmlkji

U/L  
 nmlkji
µkat/L  

 
 

58  Other tumor marker?

    
 nmlkji

yes  
 nmlkji

no  

 
 
59  Specify tumor marker:    

 
 
60  Specify value:    

 
 

61  Was tumor staging performed?

    
 nmlkji

yes  
 nmlkji

no  

 
 

62  Specify the testicular cancer stage:

    
 nmlkji

stage I - cancer remains localized to the testis  

 nmlkji
stage II - cancer involved the testis and metastasis to retroperitoneal / paraaortic lymph nodes  

 nmlkji
stage III - the cancer involves the testis and metastasus beyond the retroperitoneal and paraaortic lymph nodes  

 
 

63  Is a copy of the pathology report attached?

    
 nmlkji

yes  
 nmlkji

no  

 
 

64  Was therapy given between diagnosis and the start of the preparative regimen? (Include surgery other than the initial surgery and/or neo-adjuvant and adjuvent therapy.)

    
 nmlkji

yes  
 nmlkji

no  

 
 

65  Systemic Therapy:

    
 nmlkji

yes  
 nmlkji

no  

 
 
66  Date therapy started: __ __ __ __ - __ __- __ __  

 
 
67  Date therapy stopped: __ __ __ __ - __ __- __ __  

  
 
68  Number of cycles    

 
  

gfedcb
Unknown/not applicable

  Line of Therapy (1) Questions: 65 - 116 

Form 2022 R2.0: Testicular/Germ Cell Cancer Pre-HSCT Data  
Center:  CRID: 

               CIBMTR Form 2022 revision 2.0 last updated July 2007  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 4 / 10



 
 

69  Was therapy given prior to any surgery (neoadjuvant)?

    
 nmlkji

yes  
 nmlkji

no  

 
 

70  aldesleukin (interleukin-2)

    
 nmlkji

yes  
 nmlkji

no  

 
 

71  altretamine (Hexalen)

    
 nmlkji

yes  
 nmlkji

no  

 
 

72  bleomycin (BLM, Blenoxane)

    
 nmlkji

yes  
 nmlkji

no  

 
 

73  carboplatin (Paraplatin)

    
 nmlkji

yes  
 nmlkji

no  

 
 

74  cisplatin (CDDP, Platinol)

    
 nmlkji

yes  
 nmlkji

no  

 
 

75  cyclophosphamide (CTX)

    
 nmlkji

yes  
 nmlkji

no  

 
 

76  dactinomycin (Cosmegen)

    
 nmlkji

yes  
 nmlkji

no  

 
 

77  Doxorubicin (Adriamycin)

    
 nmlkji

yes  
 nmlkji

no  

 
 

78  Doxorubicin liposomal (Doxil)

    
 nmlkji

yes  
 nmlkji

no  

 
 

79  Etoposide (VP-16, VePesid)

    
 nmlkji

yes  
 nmlkji

no  

 
 

80  Gemcitabine (Gemzar)

    
 nmlkji

yes  
 nmlkji

no  

 
 

81  Ifosfamide (Ifex)

    
 nmlkji

yes  
 nmlkji

no  

 
 

82  Mitoxantrone (Novantrone)

    
 nmlkji

yes  
 nmlkji

no  

 
 

83  methotrexate (MTX, Folex)

    
 nmlkji

yes  
 nmlkji

no  

 
 

84  paclitaxel (Taxol)

    
 nmlkji

yes  
 nmlkji

no  

 
 

85  thiotepa (Thioplex)

    
 nmlkji

yes  
 nmlkji

no  

 
 

86  vinblastine (Velban, VLB)

    
 nmlkji

yes  
 nmlkji

no  

 
 

87  other therapy

    
 nmlkji

yes  
 nmlkji

no  

 
 
88  Specify other therapy:    

Form 2022 R2.0: Testicular/Germ Cell Cancer Pre-HSCT Data  
Center:  CRID: 

               CIBMTR Form 2022 revision 2.0 last updated July 2007  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 5 / 10



 
 

89  Radiation Therapy: 

    
 nmlkji

yes  
 nmlkji

no  

 
 
90  Date therapy started: __ __ __ __ - __ __- __ __  

 
 
91  Date therapy stopped: __ __ __ __ - __ __- __ __  

 
 

92  Local / regional

    
 nmlkji

yes  
 nmlkji

no  

 
 
93  Specify total dose:    cGy (rads) 

 
 

94  Other radiotherapy site

    
 nmlkji

yes  
 nmlkji

no  

 
 
95  Specify other radiation site:    

 
 
96  Specify total dose:    cGy (rads) 

 
 

97  Fractionation schedule:

    
 nmlkji

single  
 nmlkji

single daily  
 nmlkji

multiple daily  
 nmlkji

other schedule  

 
 

98  Surgery (other than initial):

    
 nmlkji

yes  
 nmlkji

no  

 
 
99  Date of surgery: __ __ __ __ - __ __- __ __  

 
 
100  Tye of surgery:   

 
 
101  Specify other surgery type:    

 
 

102  Was this line of therapy given for stem cell priming?

    
 nmlkji

yes  
 nmlkji

no  

 
103  Best Response to Line of Therapy: 

    
 nmlkji

CCR  Continued complete response - continued absence of all disease after a complete response 

 nmlkji
CR  Complete response - absence of clinically detectable disease including normal HCG and AFP and normalization of previously abnormal radiographic studies for 

at lease one month  

 nmlkji
PR  Partial response - >=50% reduction in the sum of the perpendicular diameters of measureable lessions for >= 1 month and/or >= 50% reduction in tumor 

markers  

 nmlkji
SD  Stable disease - tumor regression not fulfilling the requirement for partial response or tumor progression < 25% increase in the bidimensionally measurable 

tumor parameters  

 nmlkji
NR  No response - < 50% reduction in disease or tumor markers 

 nmlkji
PD  Progressive disease - new lesions that prove to be viable cancer and/or rise in the pretreatment tumor markers and/or > 25% increase in measurable lesions 

that are related to progressive viable cancer  

 nmlkji
ME  Markers elevated - no measurable disease, but tumor markers elevated 

 nmlkji
NETD  Not evaluable, toxic death 

 nmlkji
NA  Not assessed  

 
 
104  Specify reason:    

 
 
105  Date response evaluated: __ __ __ __ - __ __- __ __  

 
 

106  Did patient relapse/progress following this line of therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 
107  Date of relapse/progression: __ __ __ __ - __ __- __ __  

 

Site(s) of relapse: 
 

108  central nervous system

    
 nmlkji

yes  
 nmlkji

no  

Form 2022 R2.0: Testicular/Germ Cell Cancer Pre-HSCT Data  
Center:  CRID: 

               CIBMTR Form 2022 revision 2.0 last updated July 2007  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 6 / 10



 
 

109  Liver

    
 nmlkji

yes  
 nmlkji

no  

 
 

110  lung, parenchymal

    
 nmlkji

yes  
 nmlkji

no  

 
 

111  lymph nodes, distant

    
 nmlkji

yes  
 nmlkji

no  

 
 

112  lymph nodes, retroperitoneal

    
 nmlkji

yes  
 nmlkji

no  

 
 

113  pleura

    
 nmlkji

yes  
 nmlkji

no  

 
 

114  Skin

    
 nmlkji

yes  
 nmlkji

no  

 
 

115  other site of relapse

    
 nmlkji

yes  
 nmlkji

no  

 
 
116  specify other site of relapse    

 
117  Indicate the sensitivity of the testicular carcinoma to any chemotherapeutic agent administered prior to the preparative regimen:(Response to last chemotherapy given prior to 

HSCT; chemotherapy must include ≥ 2 cycles of treatment given ≤ 6 months prior to HSCT.) 

    
 nmlkji

sensitive- ≥ 50% reduction in bidimensional diameter of all disease sites with no new sites of disease; and >= 50% decrease in tumor markers, if evaluated  

 nmlkji
resistant- <50% reduction in disease or tumor marker evaluation with chemotherapy within 6 months of HSCT  

 nmlkji
untreated- includes chemotherapy given more than 6 months prior to HSCT, or fewer than 2 treatment cycles  

 nmlkji
Unknown  

 
118  Indicate the sensitivity of the testicular carcinoma to any platinum-containing chemotherapeutic agent administered prior to the preparative regimen: (Response to last platinum 

therapy given prior to HSCT; therapy must include ≥ 2 cycles of treatment given ≤ 6 months prior to HSCT.) 

    
 nmlkji

sensitive - response to platinum with ≥ 50% reduction in bidimensional diameter of all disease sites with no new sites of disease; and > 50% decrease in tumor markers, if 
elevated (Note: a non-response to subsequent non-platinum chemotherapy does not affect designation)  

 nmlkji
resistant - <50% response to platinum therapy in disease and tumor markers, or relapse <= 6 months after last platinum chemotherapy  

 nmlkji
untreated  

 nmlkji
refractory - progression of disease within 4 weeks of last Cisplatin dose  

 nmlkji
Unknown  

 

Specify the results of any imaging performed for the following disease sites:  

Present at any time between diagnosis and HSCT? 

 
119  Abdomen -- CT

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

120  Bone -- bone scan

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

121  Bone -- CT

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

  Most Recent Disease Assessment Prior to the Start of the Preparative Regimen Questions: 117 - 140

Form 2022 R2.0: Testicular/Germ Cell Cancer Pre-HSCT Data  
Center:  CRID: 

               CIBMTR Form 2022 revision 2.0 last updated July 2007  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 7 / 10



 
 

122  Bone -- MRI

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

123  Bone -- x-ray

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

124  Chest -- CT

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

125  Chest -- x-ray

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

126  Head -- CT

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

127  Head -- MRI

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

128  Pelvis -- CT

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

129  PET scan

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

Specify the results of any imaging performed for the following disease sites:  

Present immediately prior to the start of the preparative regimen? 

 
130  Abdomen -- CT

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

131  Bone -- bone scan

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

132  Bone -- CT

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

133  Bone -- MRI

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

134  Bone -- x-ray

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

135  Chest -- CT

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

136  Chest -- x-ray

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

137  Head -- CT

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

138  Head -- MRI

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

139  Pelvis -- CT

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

Form 2022 R2.0: Testicular/Germ Cell Cancer Pre-HSCT Data  
Center:  CRID: 

               CIBMTR Form 2022 revision 2.0 last updated July 2007  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 8 / 10



 
 

140  PET scan

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

Specify the following tumor markers determined prior to the preparative regimen: 
 

141  Serum alpha-fetoprotein (AFP):

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
142  .    ng/mL 

 
 

143  Serum beta-human chorionic gonadotropin (βhCG):

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
144  .    IU/L 

 
 

145  LDH:

    
 nmlkji

Known  
 nmlkji

Not known  

  
 
146  .    

 

  
 nmlkji

U/L  
 nmlkji
µkat/L  

 
 

147  Other tumor marker?

    
 nmlkji

yes  
 nmlkji

no  

 
 
148  Specify other tumor marker:    

 
 
149  Specify value:    

 
 

150  Central nervous system

    
 nmlkji

yes  
 nmlkji

no  

 
 

151  Liver,parenchymal

    
 nmlkji

yes  
 nmlkji

no  

 
 

152  Lung

    
 nmlkji

yes  
 nmlkji

no  

 
 

153  Lymph nodes, distant

    
 nmlkji

yes  
 nmlkji

no  

 
 

154  Lymph nodes, retroperitoneal

    
 nmlkji

yes  
 nmlkji

no  

 
 

155  Pelvis

    
 nmlkji

yes  
 nmlkji

no  

 
 

156  Pleura

    
 nmlkji

yes  
 nmlkji

no  

 
 

157  Tumor markers (AFP, HCG, LDH)

    
 nmlkji

yes  
 nmlkji

no  

 
 

158  Other site:

    
 nmlkji

yes  
 nmlkji

no  

 
 
159  Specify other new site:    

 
 

160  Was a prior HSCT performed for testicular cancer?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

  Laboratory Studies Prior to the Start of the Preparative Regimen Questions: 141 - 149

Disease Status at the Last Assessment Prior to the Preparative Regimen Questions: 150 - 164

Form 2022 R2.0: Testicular/Germ Cell Cancer Pre-HSCT Data  
Center:  CRID: 

               CIBMTR Form 2022 revision 2.0 last updated July 2007  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 9 / 10



 
 

161  Is this HSCT a planned tandem HSCT?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

162  Is this HSCT in response to residual disease?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

163  What was the disease status at the last evaluation prior to the preparative regimen?

    
 nmlkji

no evidence of disease as defined surgically, tumor markers within normal limits  

 nmlkji
no evidence of disease as defined clincally, tumor markers within normal limits  

 nmlkji
tumor marker elevation only  

 nmlkji
residual tumor mass, tumor markers within normal limits  

 nmlkji
residual tumor mass, elevated tumor markers  

 nmlkji
Not evaluable  

 nmlkji
Unknown  

 
 
164  Date of the most recent assessment for disease status prior to the preparative regimen: __ __ __ __ - __ __- __ __  

  
 
First Name:    

 
Last Name:    

  
 
Phone:    

 
Fax:    

 
 
E-mail address:    

Form 2022 R2.0: Testicular/Germ Cell Cancer Pre-HSCT Data  
Center:  CRID: 

               CIBMTR Form 2022 revision 2.0 last updated July 2007  
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 10 / 10